Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver. Statins also have beneficial pleiotropic effects on the atherosclerotic process that are independent of their ability to lower lipid values. However, the levels of low-density lipoprotein cholesterol (LDL-C) in most hypercholesterolemic patients at high risk for cardiovascular disease do not reach the goals proposed by guidelines even when prescribed with statins. Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins. However, its effect on cardiovascular events remains unknown. We reviewed the effects of ezetimibe on cardiovascular diseases, in particular, vascular endothelial function, which is initially impaired during the atherogenetic process and an important predictor of cardiovascular events. Increasing evidence suggests that ezetimibe improves endothelial function and nitric oxide availability, and reduces inflammation as well as oxidative stress. However, this mechanism has not been clarified and limited, large trials and cohort studies have not shown that this agent prevents cardiovascular events. Ezetimibe has just recently become commercially available, which might explain the paucity of evidence regarding its benefits and effects on cardiovascular morbidity and mortality.
Introduction
Cardiovascular diseases based on atherosclerosis comprise one of the most frequent causes of worldwide mortality [1] . The initiation of atherosclerotic disease is closely related to prolonged dyslipidemia, and reducing levels of low-density lipoprotein cholesterol (LDL-C) is a cornerstone in minimizing cardiovascular events in high-risk patients. Guidelines from the National Cholesterol Education Program (NCEP) Adult Treatment Program (ATP) III in the United States [2] and the Joint Task Force of
European and other Societies on Cardiovascular Disease Prevention in Clinical Practice
in Europe [3] continue to identify elevated LDL-C as the primary target for lipid-modifying therapy. Furthermore, the subsequent ATP-III update in 2004 suggested that the optimal LDL-C level in high-risk individuals might be lower (< 70 mg/dl) than that of current treatment guidelines (< 100 mg/dl) [4] . Despite these guidelines, many hypercholesterolemic patients on lipid-lowering therapy do not achieve the recommended LDL-C goals [5, 6] . This treatment gap is particularly evident among high-risk patients with coronary heart disease (CHD). Foley et al. [7] demonstrated that 52% of high-risk hyperlipidemic patients did not achieve the LDL-C goal with an initial dose of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and that 86% of these patients had still not reached the goal after 6 months. Dembowski et al. showed that only 18% of these patients achieved the LDL-C treatment goal with statin monotherapy [8] . One reason is that the initiation dose of statins is most effective and doubling the dose achieves only a 6% additional reduction in LDL-C levels [9] .
Statins lower cholesterol through inhibiting cholesterol synthesis. However, the intestinal absorption of dietary and biliary cholesterol is also a major source of 4 cholesterol that affects lipid profiles [10] . Therefore, the inhibition of cholesterol absorption in the intestine is considered to be a potentially complementary component of lipid management.
Ezetimibe was discovered as a potential inhibitor of acylcoenzyme A: cholesterol acyltransferase and it is the first cholesterol absorption inhibitor to actually inhibit biliary and dietary cholesterol absorption from the small intestine. This agent specifically blocks the cholesterol transporter, Niemann-Pick-like protein 1, which is enriched in the brush border membrane of the small intestine. The inhibition of cholesterol absorption consequently decreases cholesterol delivery to the liver, reduces hepatocyte cholesterol stores, increases liver expression of LDL receptors and increases serum LDL production and clearance, resulting in a fall in serum LDL-C levels [11, 12] . Ezetimibe reduces cholesterol absorption by 40 to 50% [13] , and it reduces LDL-C levels by about 18% [14] . Co-administration of ezetimibe and statin significantly reduces LDL-C levels by 18 to 25% compared to statin monotherapy [15] .
This synergistic effect can help more patients with hyperlipidemia to achieve LDL-C targets. Gagne et al. [16] reported that only 19% of patients reach treatment goals on statin monotherapy whereas adding ezetimibe increases this proportion to 72%. This might result in a decrease in the incidence of future cardiovascular events.
Impaired vascular endothelial function is one initial step in the progress of atherosclerosis, which leads to the development of cardiovascular disease. Therefore, endothelium dysfunction is an important predictor of cardiovascular events. This chapter reviews the effects of ezetimibe on endothelial function.
Endothelial function
The vascular endothelium is a continuous layer of cells that separates blood from 5 vessel walls and it plays an important role in many physiological functions including the regulation of vasomotor tone and the maintenance of vascular homeostasis [17] [18] [19] [20] [21] [22] [23] [24] [25] .
These processes involve the production of vasoconstrictive and vasodilating factors from endothelial cells. Endothelium-derived relaxing factors comprise nitric oxide (NO), prostacyclin and endothelium-derived hyperpolarizing factor. Nitric oxide is very important and it is mediated by the endothelium isoform of NO synthase (endothelial NO synthase, eNOS). The production of NO derived via eNOS protects the endothelium from vascular damage by inhibiting vascular smooth muscle cell proliferation, platelet and leukocyte activation and adhesion, oxidative stress and the degranulation of proinflammatory vesicles. In addition, NO inhibits both the release and action of endothelin-1, a potent vasoconstrictive peptide in the endothelium, which facilitates a proatherogenic phenotype [24] [25] [26] [27] [28] [29] [30] . Thus, NO plays a pivotal role in maintaining endothelial structural integrity and functional activity, which subsequently protects against the development of atherosclerotic vascular disease. Despite the importance of the intact endothelium and the maintenance of endothelial integrity, the indicate that eNOS-derived NO production is crucial for maintaining endothelial health.
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The bioavailability of vasodilators, especially NO is reduced, whereas that of endothelial-derived contracting factors is increased in endothelial dysfunction. This imbalance predisposes the vasculature to vasoconstriction, leukocyte adhesion, platelet activation, pro-oxidation, thrombosis, inflammation and atherosclerosis [23, 25, 43] .
Endothelial dysfunction probably precedes the clinical manifestations of cardiovascular disorders such as hypertension, dyslipidemia, and diabetes. Cholesterol levels have an intimate and linear relationship with coronary artery disease risk.
Endothelium-dependent vascular relaxation is impaired and vascular superoxide production is increased in hypercholesterolemic apoE-knockout mice. This is due to a deficiency of tetrahydrobiopterin (BH4), an essential cofactor for NOS in the aortas of these knockout mice compared to wild-type mice, but dietary BH4 supplementation appears to reduce superoxide production and restore NO synthesis [44] . Reduced levels of BH4 induce "eNOS uncoupling", with the resultant production of superoxide, leading to endothelial dysfunction [25, 45] [55] , and estrogen replacement therapy for post menopausal women [56] can improve endothelial function.
Hypercholesterolemia is one of the most important risk factors for cardiovascular disease because LDL-C, especially oxidized LDL, contributes to the initiation of plaque formation from the early stage of atherogenesis [57, 58] . During this process, protein kinase C and nuclear factor kinase-kB (NF-kB) are initially activated in cells, where they up-regulate the local production of angiotensin II, as well as the expression of enzymes that produce oxidative stress as well as endothelial cell surface adhesion molecules [59] . These play key roles in the development of endothelial dysfunction.
Lipid lowering per se is associated with improved endothelial function regardless of the choice of therapeutic strategy; for example, LDL apheresis improves endothelial-dependent vasodilation [60] .
Statins are potent lipid-lowering agents and considerable evidence shows that statins have beneficial pleiotropic effects on cardiovascular diseases that are independent from their lipid-lowering effects [61] [62] [63] [64] . These involve improved endothelial function, attenuation of the inflammatory process and normalization of the coagulation system, leading to a reduction in cardiovascular disease morbidity and down-regulates eNOS expression [66] . This posttranslational modification promotes membrane-protein-protein interactions and influences several intracellular signaling pathways [67, 68] . Statins diminish the formation of isoprenylated and geranylgeranylated proteins. Thus, the statin-induced inhibition of isoprenoid formation on Rho proteins might increase eNOS expression. Caveolin is a scaffolding protein on lipid rafts in the plasma membrane that blocks eNOS access to its cofactor and substrate, resulting in reduced NO production, which is reversed by statins [69, 70] .
The beneficial effects of statins are also associated with less reactive oxygen species
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(ROS) being produced in the vasculature through inhibiting the activation of oxidant system NADPH oxidase [71, 72] . The inhibition of Rac-1 prenylation appears to mediate the down-regulation of NADPH oxidase [73] .
Ezetimibe is a novel lipid lowering agent, which unlike statins, selectively inhibits biliary and dietary cholesterol absorption from the small intestine. Increasing evidence has shown that this agent, when applied alone or in combination with statins, decreases LDL-C levels and the probability of cardiovascular events [74, 75] . The following paragraph reviews the effects of ezetimibe on clinically detectable endothelial function.
Clinical effect of ezetimibe on endothelial function
Endothelial dysfunction is an early event in the pathogenesis of atherosclerosis, and it predicts cardiovascular complications in patients with coronary artery disease (CAD) [76, 77] . Therefore, the assessment of vascular endothelial function is clinically with high-resolution ultrasonography [83] . Forearm blood flow is influenced mainly by the endothelial function of resistant vessels, whereas FMD reflects mainly that of the conduit arteries [84] . Although these techniques are not significantly associated, endothelial-dependent vasodilation with either of them is related to endothelial function in coronary arteries [85, 86] . Thus, these techniques allow the minimally-or non-invasive assessment of endothelial function in humans, and thus alter the morbidity or mortality of patients with atherosclerosis.
Several studies have examined whether ezetimibe has effects other than cholesterol-lowering or improves endothelial function measured as forearm vasodilator responses and/or FMD. Bulut et al. [87] showed that switching from atorvastatin 40 to 10 mg/day combined with ezetimibe 10 mg/day, induced a significant additional reduction in cholesterol and improved endothelial function in patients with metabolic syndrome. Olijhoek et al. [88] demonstrated that post-fat load FMD was preserved in patients with metabolic syndrome taking simvastatin and ezetimibe (both 10 mg/day), findings that were contrary to those generated by 80 mg of simvastatin. Settergren et al. [89] showed that FMD after 6 weeks increased from 4.3 to 5.5% in patients given simvastatin and ezetimibe (both 10 mg/day) and from 4.3 to 5.2% in those given simvastatin (80 mg/day). However, the increase in FMD between the groups did not significantly differ. These findings suggest that low-dose statin combined with ezetimibe is more (or similarly) effective on endothelial function than high-dose statin.
In contrast, monotherapy with statin, but not ezetimibe, improves endothelial function Table 1 .
Collectively, ezetimibe monotherapy is less effective than statin monotherapy in improving endothelial function, but the effect of combining ezetimibe with low-dose statin is greater than, or similar to that of high-dose statin. Ezetimibe might be more effective in the primary prevention of CAD, such as in avoiding metabolic syndrome.
Whether the effects of ezetimibe on endothelial function are dependent or independent of cholesterol-lowering remain unknown. However, that improvements in endothelial function are direct effects of ezetimibe on vascular endothelial cells is unlikely because only a little ezetimibe is absorbed into the blood circulation.
Effect of ezetimibe on NO
Ezetimibe, especially in combination with statin, might exert a favorable effect on endothelial function in the clinical setting. Ezetimibe might modulate the pathway of NO mediated by eNOS, which is a key factor in maintaining the integrity of the vascular endothelium. However, few reports have described an association between ezetimibe and NO.
One study using an animal model has shown that ezetimibe reduces plaque progression by 47 and 27% in male and female apoE knockout mice, respectively, and by 34 and 26% in male and female apoE/eNOS double-knockout mice, respectively, compared to animals of the same genotype fed with a western diet [94] . Furthermore, the same study showed that ezetimibe did not influence eNOS protein expression or NO production in blood vessels of apoE knockout mice. Thus, the anti-atherosclerotic effect of this agent seems largely eNOS independent, although the effects might be . In rats orally pretreated with high-dose atorvastain and simvastatin (both 10 mg/kg/day), the sizes of myocardial infarctions induced by ischemia-reperfusion injury were decreased whereas activity levels of calcium-dependent NOS including eNOS were significantly increased compared to sham treated rats. In contrast, infarction size was not reduced in rats pretreated with low-dose simvastatin (2 mg/kg/day) alone, ezetimibe (1 mg/kg/day) alone or a combination of the two. Calcium-dependent NOS activity was reduced by low-dose monotherapy with either simvastatin or ezetimibe, and slightly increased by a combination of both. These findings suggest that ezetimibe alone or in combination with low-dose statin has no effect on the eNOS bioavailability that can protect against myocardial infarction in rats. Lipid-lowering mediates these favorable effects of ezetimibe on atherosclerosis as well as direct and/or indirect vascular protective effects.
An association between ezetimibe with NO in humans has also been described. found that the effects on EPC levels in this population were similar between low-dose simvastatin plus ezetimibe and high-dose simvastatin that achieve similar LDL-C levels.
This suggests that LDL-C reduction is more important than the pleiotropic effects of statins. Thus, ezetimibe combined with a statin might result in a synergistic effect on EPC functions.
Effect of ezetimibe on inflammation
C-reactive protein (CRP), mainly produced by hepatocytes in response to IL-6 and then secreted into the systemic circulation, is an acute-phase reactant in humans [116] .
Elevated CRP levels are related to impaired endothelial function and comprise a powerful predictor of future cardiovascular events. Furthermore, studies in vitro have
shown that CRP modulates the activity and expression of several factors implicated in atherogenesis; for example CRP down-regulates eNOS and decreases NO release, which facilitates endothelial dysfunction [117] .
Studies that have examined the effect of statin alone and a statin-ezetimibe combination on CRP are listed in Table 2 . Pearson et al. [118] reported the effects of ezetimibe alone or in combination with statins on CRP and LDL-C determined from two pooled analyses of randomized, placebo-controlled trials in patients with hypercholesterolemia.
The investigation included six studies of ezetimibe monotherapy and seven of ezetimibe added to ongoing statin therapy. Ezetimibe monotherapy induced a mean 1% decrease in CRP after 12 weeks; the mean difference from placebo was 6% (p = 0.09). In contrast, ezetimibe added to baseline statin resulted in a significant additional reduction in CRP (mean treatment difference was 10%, P < 0.001) after 6-8 weeks. Thus, although adding ezetimibe to statin obviously enhances CRP reduction, the role of ezetimibe monotherapy is less well defined.
Efrati et al. [119] reported that adding ezetimibe to 40 mg of simvastatin reduced CRP to levels below that achieved by doubling the statin dose. However, ezetimibe combined with rosuvastatin significantly reduced CRP levels compared to rosuvastatin alone [120] , whereas a single tablet comprising ezetimibe/simvastatin induced a greater reduction in LDL-C levels relative to rosuvastatin but a similar change in hs-CRP levels in both groups [121] . Although combination therapy seems to be superior to statin monotherapy in terms of lowering LDL-C, a superior effect on CRP remains
contentious. Even studies that demonstrated a favorable effect of combination therapy on CRP also found a significantly larger reduction in LDL-C. Therefore, whether the effect of ezetimibe on CRP is dependent or independent of its cholesterol-lowering effect remains unknown. To understand the differences in CRP reduction among therapies that achieve similar levels of LDL reduction is important because clinicians may choose lipid-lowering therapy based not only on a reduction in LDL, but also in CRP.
Thus, ezetimibe might have synergistic effects on levels of CRP as well as of LDL-C when combined with statins, although whether the effect on CRP is dependent or independent of its cholesterol-lowering effect remains undetermined.
Effect of ezetimibe on oxidative stress
Oxidative stress caused by enhanced production of reactive oxygen species (ROS) and/or decreased antioxidant levels plays an important role in the pathophysiology of vascular endothelial dysfunction, resulting in abnormal vasorelaxation. Several reports describe the effect of ezetimibe on oxidative stress.
Animal studies have shown that ezetimibe suppresses ROS production in the aorta
[97] and liver [122] . Ezetimibe monotherapy exerted the highest increase in the hepatic alpha-tocopherol/maleic dialdehyde ratio (means antioxidant/oxidant ratio), compared to monotherapy with other insulin-sensitizing agents, such as rosiglitazone, metoformin and valsartan in a methionine choline-deficient diet rat model of non-alcoholic fatty liver disease [123] . This suggests that ezetimibe has antioxidant effects. Hussein et al. [124] due to small number of subjects, and differences as well as stabilities of oxidative stress markers in the previous studies.
Effect of ezetimibe on cardiovascular events in clinical trials
Ezetimibe, especially in combination with statin, might ameliorate endothelial dysfunction. However, whether ezetimibe impacts morbidity and mortality in patients 
Conclusions
Statin alone is currently insufficient for patients with hypercholesterolemia, especially those at high risk for cardiovascular disease, to achieve guideline-defined LDL-C goals. Ezetimibe is a potent LDL-C lowering agent, and, when combined with FMD, flow-mediated vasodilatation in brachial artery; FDD, flow-dependent dilation in radial artery; FBF, forearm blood flow responded by acetylcholine R, randomized; DB, double-blind; CO, cross-over; Mets, metabolic syndrome; CHF, congestive heart failure; RA, rheumatoid arthritis; CAD, coronary artery disease; IGT, impaired glucose tolerance; DM, diabetes mellitus. 
